VivoSim Labs Inc (VIVS) - Cash per Share

Corporate emblem and logo of VivoSim Labs (VIVS)

Demand for 3D bioprinting remains stable as it optimizes drug development costs for pharma behemoths. Quarterly cash per share confirms this trend, where 0.43 determines this parameter level. However, pre-commercial status and R&D expenses preclude the generation of free cash flow, while a lack of capital restricts VivoSim Labs Inc (VIVS) expansion within the high-tech segment.

VIVS - Organovo Cash per Single Share over the range 04/25/2025 - 11/20/2026

Analytical breakdowns for VivoSim Labs Inc

- cash position and cash flow details:
General company analysis:VIVS, Organovo Holdings
Original product of Organovo Holdings Inc.

The metric is calculated by dividing total liquid assets by the number of shares outstanding to determine the security's intrinsic value. The trend of this metric depends directly on the purity of cash flows in quarterly reports. By analyzing the cash level per share, an investor assesses the balance between a financial cushion and capital efficiency. For VivoSim Labs Inc (VIVS), excess liquidity may signal an underutilization of resources. However, a stable cash reserve supports the development of proprietary bioprinting technologies, consolidating the company's position within the pharmaceutical laboratory infrastructure.